Daniel Morillo

678 total citations
30 papers, 275 citations indexed

About

Daniel Morillo is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Daniel Morillo has authored 30 papers receiving a total of 275 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 13 papers in Hematology and 9 papers in Molecular Biology. Recurrent topics in Daniel Morillo's work include CAR-T cell therapy research (10 papers), Multiple Myeloma Research and Treatments (9 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Daniel Morillo is often cited by papers focused on CAR-T cell therapy research (10 papers), Multiple Myeloma Research and Treatments (9 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Daniel Morillo collaborates with scholars based in Spain, United States and Canada. Daniel Morillo's co-authors include Paula Rodríguez‐Otero, María‐Victoria Mateos, Albert Oriol, Raúl Córdoba, Valentina Boni, Maria Krevvata, Sung‐Soo Yoon, Kihyun Kım, Jill Vanak and Moshe E. Gatt and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Daniel Morillo

25 papers receiving 271 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Morillo Spain	9	152	141	98	66	60	30	275
Efstathios Koulieris Greece	10	141 0.9×	103 0.7×	88 0.9×	29 0.4×	46 0.8×	24	262
Cinnie Yentia Soekojo Singapore	10	176 1.2×	110 0.8×	202 2.1×	14 0.2×	43 0.7×	30	298
Thomas G Martin United States	10	369 2.4×	263 1.9×	318 3.2×	45 0.7×	23 0.4×	19	504
A.-L. Taksin France	6	219 1.4×	107 0.8×	103 1.1×	63 1.0×	33 0.6×	6	360
Peter Tan Australia	10	126 0.8×	55 0.4×	109 1.1×	12 0.2×	85 1.4×	18	252
Sung‐Soo Yoon South Korea	9	152 1.0×	91 0.6×	120 1.2×	12 0.2×	35 0.6×	54	272
Hamdi Sati United Kingdom	5	160 1.1×	138 1.0×	74 0.8×	26 0.4×	32 0.5×	9	229
Agne Paner United States	9	160 1.1×	114 0.8×	217 2.2×	11 0.2×	13 0.2×	33	282
Serena Rocchi Italy	9	255 1.7×	157 1.1×	180 1.8×	18 0.3×	11 0.2×	31	301
Marcelo Capra Brazil	11	211 1.4×	202 1.4×	129 1.3×	61 0.9×	24 0.4×	40	336

Countries citing papers authored by Daniel Morillo

Since Specialization

Citations

This map shows the geographic impact of Daniel Morillo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Morillo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Morillo more than expected).

Fields of papers citing papers by Daniel Morillo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Morillo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Morillo. The network helps show where Daniel Morillo may publish in the future.

Co-authorship network of co-authors of Daniel Morillo

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Morillo. A scholar is included among the top collaborators of Daniel Morillo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Morillo. Daniel Morillo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Doger, Bernard, Daniel Morillo, Balázs Győrffy, et al.. (2025). Prolonged survival in a patient with pbrm1 mutated metastatic cholangiocarcinoma receiving tazemetostat. npj Precision Oncology. 9(1). 331–331. 1 indexed citations

Trněný, Marek, Raúl Córdoba, Sven de Vos, et al.. (2025). ABCL-404: Epcoritamab + R-ICE in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Eligible For Autologous Stem Cell Transplantation (ASCT): EPCORE NHL-2. Clinical Lymphoma Myeloma & Leukemia. 25. S736–S736.

Garciaz, Sylvain, Pierre Péterlin, Daniel Morillo, et al.. (2025). γ9δ2 T-cell (γ9δ2TC) activation with ICT01 and azacitidine-venetoclax (Aza-Ven) induces high rates of remission and overall survival in patients with newly diagnosed (ND) acute myeloid leukemia (AML): Results from the phase 1/2 study eviction. Blood. 146(Supplement 1). 652–652.

Falchi, Lorenzo, Fritz Offner, Sven de Vos, et al.. (2025). Fixed-duration epcoritamab + R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: Results from the EPCORE NHL-2 trial. Blood. 146(Supplement 1). 1955–1955.

Maiti, Abhishek, Pierre Péterlin, Daniel Morillo, et al.. (2024). ICT01, an Investigational γ9δ2 T Cell Activator, Added to Azacitidine-Venetoclax Achieves Frequent and Early Complete Remissions in Adults with AML Unfit for Intensive Induction Chemotherapy: Interim Results from the Ongoing Open-Label, Randomized Phase 1 Study Eviction. Blood. 144(Supplement 1). 2876–2876. 1 indexed citations

Morillo, Daniel, Carmen Martínez Chamorro, Luciano J. Costa, et al.. (2024). P-058 Cytokine Release Syndrome in Patients Receiving Alternative Step-Up Doses of Talquetamab for Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study. Clinical Lymphoma Myeloma & Leukemia. 24. S74–S75. 1 indexed citations

López‐García, Alberto, Sandra Gómez‐Talavera, Daniel Morillo, et al.. (2024). Predictive Factors of Therapy-Related Cardiovascular Events in Patients with Lymphoma Receiving Anthracyclines. SHILAP Revista de lepidopterología. 12(2). 23–23. 1 indexed citations

Tahir, Stephen K., Emiliano Calvo, Benedito A. Carneiro, et al.. (2023). Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia. Blood. 141(17). 2114–2126. 9 indexed citations

Córdoba, Raúl, et al.. (2023). Feasibility of Telemedicine in the Management Strategy of Patients With Lymphoma Amid the COVID-19 Pandemic in Spain: Prospective Observational Study. JMIR Formative Research. 7. e34128–e34128. 2 indexed citations

10.

Cohen, Yaël C., Daniel Morillo, Moshe E. Gatt, et al.. (2023). POSTER: MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 23. S226–S226. 1 indexed citations

11.

Cohen, Yaël C., Daniel Morillo, Moshe E. Gatt, et al.. (2023). MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 23. S478–S479. 1 indexed citations

12.

Dholaria, Bhagirathbhai, Katja Weisel, María‐Victoria Mateos, et al.. (2023). POSTER: MM-161 Talquetamab + Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated TRIMM-2 Results. Clinical Lymphoma Myeloma & Leukemia. 23. S216–S216. 1 indexed citations

13.

Dholaria, Bhagirathbhai, Katja Weisel, María‐Victoria Mateos, et al.. (2023). Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.. Journal of Clinical Oncology. 41(16_suppl). 8003–8003. 41 indexed citations

14.

López‐García, Alberto, Ignacio Mahíllo, Daniel Morillo, et al.. (2023). Frailty assessment to individualize treatment in older patients with lymphoma. European Geriatric Medicine. 14(6). 1393–1402. 7 indexed citations

15.

Cohen, Yaël C., Daniel Morillo, Moshe E. Gatt, et al.. (2023). First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 41(16_suppl). 8002–8002. 58 indexed citations

16.

Diamond, Jennifer R., Valentina Boni, Emerson A. Lim, et al.. (2022). First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy. Clinical Cancer Research. 28(7). 1285–1293. 30 indexed citations

17.

Moreno, Vı́ctor, Raúl Córdoba, Daniel Morillo, et al.. (2021). Safety and efficacy of VIP152, a CDK9 inhibitor, in patients with double-hit lymphoma (DHL).. Journal of Clinical Oncology. 39(15_suppl). 7538–7538. 6 indexed citations

18.

Miguel, Maria J. de, Bernard Doger, Valentina Boni, et al.. (2020). Increased vulnerability of clinical research units during the COVID‐19 crisis and their protection. Cancer. 126(17). 3907–3911. 10 indexed citations

19.

González‐Vicent, Marta, Jaime Sanz, José Luís Fuster, et al.. (2018). Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): A retrospective analysis and a proposal of treatment on behalf of the Grupo Español De Trasplante de Medula Osea en Niños (GETMON) and the Grupo Español de Trasplante Hematopoyetico (GETH). Transfusion Medicine Reviews. 32(3). 179–185. 28 indexed citations

20.

Ojeda, Emilio, Rafael Forés, Miguel Pastrana, et al.. (2014). Paroxysmal nocturnal hemoglobinuria: a singleSpanish center's experience over the last 40 yr. European Journal Of Haematology. 93(4). 309–319. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact